Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and health care issues, announced today that anti-angiogenic agents hold significant potential for the treatment of cancer, allowing them to command premium pricing. Sales of anti-angiogenic therapies could increase to between $1 billion and $3 billion by 2011. The report entitled Angiogenesis-Based Therapies specifically finds that non-small-cell lung and breast cancer will benefit the most from angiogenesis-based therapies.
"The oncology markets are changing dramatically, moving away from non- specific and highly toxic chemotherapeutic regimes of the past towards more targeted agents," said Julie Curran, analyst, Decision Resources. "Because angiogenesis inhibitors have the potential to treat multiple types of cancers with little systemic toxicity, their commercial impact may be vast there since cancer markets historically have tolerated high-price agents."
Significant commercial opportunity for angiogenesis inhibitors also exists outside the oncology sphere, in diseases such as Rheumatoid Arthritis (RA) and psoriasis. Although the RA and psoriasis markets are not as lucrative as oncology indication markets, angiogenesis inhibitors may still impact them because they satisfy some aspects of current unmet need. Additionally, pro- angiogenic factor development is opening up new therapeutic options in cardiovascular disease indications.
Angiogenesis is the biological function of the formation of blood vessels. Normal, physiological angiogenesis is a tightly regulated process occurring during embryonic development and adult life. In contrast, persistent, uncontrolled angiogenesis can contribute to pathological situations. In particular, angiogenesis plays a role in the pathology of cancers, (both solid tumors, such as colorectal, breast, prostate and lung and hematological tumors, such as leukemias), rheumatoid arthritis, psoriasis and ocular disease and also occurs in cardiovascular diseases following ischemia.
About Pathways and Processes from Decision Resources
Angiogenesis is the second report from Pathways and Processes, a new advisory service that focuses on cellular and molecular pathways. The reports provide insight into cutting-edge developments relating to drug targets that have the potential to significantly change treatment practice and impact multiple pharmaceutical markets.
About Decision Resources
Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 email@example.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563, or
Web site: http://www.dresources.com/